08:04 AM EST, 11/06/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) Thursday reported a second-quarter loss even as revenue rose.

Net loss was $3.8 million, or $0.04 per share, compared with net income of $85,000 or nil per share, in the prior year period. Knight said the wider loss was due to higher taxes, and a net loss of $4.6 million based on the revaluation of financial assets.

Revenue jumped 32% to $121.5 million. The Paladin and Sumitomo portfolios contributed to $25 million of incremental revenue, the company said.